Document is current
Any future updates will be listed below
-
Authors
Hunt, Allison L.
Randall, Jamie
Ogata, Jonathan D.
Johnston, Laura
Swain, Whitney
Melvin, Savannah
Sharma, Meenakshi
Calvert, Valerie
Maxwell, G. Larry
Bateman, Nicholas W.
Petricoin, Emanuel F.
Conrads, Thomas P.
Cannon, Timothy L.
-
Funding
Funding for this research was provided by:
Inova Schar Molecular Tumor Board Philanthropy funds
- License Information
-
More Information
Article History
Received: 10 October 2025
Accepted: 20 February 2026
First Online: 5 March 2026
Competing interests
: T.P.C. is a Thermo Fisher Scientific, Inc. SAB member and receives research funding from AbbVie. E.F.P. receives research funding from Genentech, Pfizer, Mirati, Springworks Therapeutics, Deciphera, AbbVie, and is a co-inventor of the RPPA Technology described herein, and related HER2 biomarker patents, and receives royalties on the related license agreements.
